|
Re: Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal
|
8
|
Resverlogix Corp.
|
Nov 28, 2018 09:06AM
|
|
Re: Some calculations on efficacy
|
8
|
Resverlogix Corp.
|
May 31, 2018 08:34PM
|
|
Re: Questions for Q1 webcast
|
8
|
Resverlogix Corp.
|
Mar 05, 2016 12:07PM
|
|
A fair and optimistic write up on BETonMACE
|
8
|
Resverlogix Corp.
|
Nov 22, 2019 06:58AM
|
|
Re: You're right 10bagr, you didn't sway me....
|
8
|
Resverlogix Corp.
|
Jan 31, 2019 11:05PM
|
|
Third Eye, AHA, US Listing
|
8
|
Resverlogix Corp.
|
Sep 08, 2019 08:35AM
|
|
Modulating ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
|
8
|
Zenith Epigenetics
|
Sep 01, 2018 10:59PM
|
|
Re: AACR
|
8
|
Zenith Epigenetics
|
Apr 08, 2019 11:46AM
|
|
Zenith Epigenetics Announces Clinical Collaboration with Astellas
|
8
|
Zenith Epigenetics
|
Apr 22, 2021 04:34PM
|
|
Re: To Those Attending the ASM or in contact with the Company....
|
8
|
Resverlogix Corp.
|
Oct 31, 2019 07:06AM
|
|
Re: AAIC and MD&A
|
8
|
Resverlogix Corp.
|
Jul 25, 2018 09:38AM
|
|
Alkaline Phosphatase and Alzheimer's Disease
|
8
|
Resverlogix Corp.
|
Jun 15, 2018 10:33AM
|
|
Apabetalone’s Beneficial Effects on COVID-19 Published in Prestigious Scientific Journal Cell
|
8
|
Resverlogix Corp.
|
Mar 17, 2021 08:05AM
|
|
Re: A few upcoming conference appearances
|
8
|
Resverlogix Corp.
|
Apr 12, 2021 11:07AM
|
|
MD&A March 26, 2018
|
8
|
Zenith Epigenetics
|
Mar 27, 2018 06:35PM
|
|
Still waiting for that BETonMACE CKD sub-study 7 months later
|
8
|
Resverlogix Corp.
|
Jun 11, 2020 09:37AM
|
|
Zenith NYAS Symposium notes
|
8
|
Zenith Epigenetics
|
Apr 29, 2016 12:50PM
|
|
BET inhibitor and BRD4 papers keep piling up
|
8
|
Resverlogix Corp.
|
Sep 23, 2017 06:11PM
|
|
Re: Third Eye, AHA, US Listing
|
8
|
Resverlogix Corp.
|
Sep 11, 2019 02:39PM
|
|
Speculation is warranted
|
8
|
Resverlogix Corp.
|
Aug 25, 2016 12:45PM
|
